As someone who does not qualify for Trikafta®, I took particular interest in the first plenary of the North American Cystic Fibrosis Conference, which discussed potential treatments for people with nonsense and rare mutations. I learned that researchers are exploring a variety of options, and some early research has shown promising results.
Site Search
Showing 1 - 3 of 3 results
Caroline Starnes
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
News
|
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
|
2 min read